CEL-SCI Corp Stock Price, News & Analysis

CEL-SCI Corporation (NYSE American: CVM) has announced the pricing of a public offering of 1,111,200 shares of common stock at $9.00 per share, aiming to raise approximately $10 million in gross proceeds. The offering, expected to close on August 29, 2025, is being conducted through ThinkEquity as the sole placement agent.

The company plans to use the proceeds to fund the continued development of Multikine, their investigational cancer immunotherapy treatment that has received FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma patients. Multikine has been administered to over 740 patients and is designed to boost patients' immune systems before conventional cancer treatments begin.

CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has announced its intention to conduct a best-efforts public offering of common stock and/or pre-funded warrants. The offering will be made through a shelf registration statement that was declared effective on August 12, 2025.

The company plans to use the proceeds to fund the continued development of its Multikine product, along with general corporate purposes and working capital. ThinkEquity is serving as the sole placement agent for this offering. The final size and terms of the offering will depend on market conditions.

CEL-SCI (NYSE American: CVM) reported its fiscal Q3 2025 results and significant developments for its cancer treatment Multikine. The company is poised to enter a crucial partnership in Saudi Arabia, where Multikine could become commercially available within 60 days following Breakthrough Medicine Designation approval.

Key financial highlights include a net loss of $5.7 million ($1.36 per share) for Q3, improved from $7.5 million loss year-over-year. The company raised $10.7 million through two stock offerings in May and July 2025. Notable developments include management's purchase of 32,116 restricted shares and preparation for a 212-patient Confirmatory Registration Study for Multikine in head and neck cancer patients.

Clinical data shows Multikine reduced death risk by 66% in PD-L1 low/negative patients, positioning it strongly in the market segment.

CEL-SCI Corporation (NYSE:CVM) has announced a significant advancement for its cancer immunotherapy Multikine in Saudi Arabia. The company has signed an MOU with a leading Saudi pharmaceutical company that has filed for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA).

The designation, which has an approximate 60-day review timeline, would enable immediate patient access and reimbursement/sale of Multikine in Saudi Arabia. In Phase 3 trials, Multikine demonstrated remarkable efficacy, increasing 5-year survival rates to 73% versus 45% in standard care, while reducing death risk from 55% to 27% in head and neck cancer patients.

A final partnership agreement is expected in Q3 2025, with several Saudi funds expressing interest in investing in CEL-SCI and a potential joint venture for the MENA region.

CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has completed a $5.7 million best-efforts offering of 1,500,000 common stock shares at $3.82 per share, priced at-the-market under NYSE American rules.

The company plans to use the net proceeds to fund the continued development of Multikine, their investigational immunotherapy treatment designed to boost patients' immune systems before cancer treatments. Multikine has received FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma patients and has been administered to over 740 patients.

ThinkEquity served as the sole placement agent for the offering, which was conducted under a shelf registration statement previously filed with the SEC.

CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has announced a $5.7 million best-efforts offering of 1,500,000 common stock shares priced at $3.82 per share. The offering, expected to close on July 14, 2025, is priced at-the-market under NYSE American rules.

The company plans to use the proceeds to fund the continued development of Multikine, their investigational immunotherapy treatment for head and neck cancer that has received FDA Orphan Drug designation, along with general corporate purposes and working capital. ThinkEquity is serving as the sole placement agent for this offering, which is being conducted under a shelf registration statement filed with the SEC.

CEL-SCI Corporation (NYSE:CVM) has announced a significant partnership agreement with a leading Saudi Arabian pharmaceutical company for Multikine, their immunotherapy treatment for head and neck cancer. The partnership encompasses regulatory and commercial activities in Saudi Arabia, with plans to file for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA).

The agreement could enable rapid market access, with patient access and reimbursement possible within approximately 60 days following the filing. Several Saudi funds have expressed interest in investing in CEL-SCI and a potential joint venture to serve the broader Middle East and North Africa (MENA) market. Clinical data shows Multikine increased 5-year survival rates to 73% versus 45% in patients treated with standard care alone, reducing the risk of death from 55% to 27%.

The FDA has approved Merck's Keytruda for treating PD-L1 positive head and neck cancer patients, which CEL-SCI (NYSE: CVM) views as a positive precedent for its Multikine therapy. While Keytruda showed a 30% reduction in recurrence risk for PD-L1 positive patients without improving overall survival, CEL-SCI's Multikine demonstrated a 66% reduction in death risk for PD-L1 low/negative patients, extending 5-year survival rates from 45% to 73%. The FDA's approval of Keytruda based on interim Phase 3 results suggests potential accelerated approval pathway for Multikine, which has received FDA clearance for a 212-patient confirmatory Registration Study. Notably, about 70% of patients in CEL-SCI's Phase 3 study had low to zero PD-L1 levels, and Multikine-treated patients showed an almost 4-year median overall survival advantage compared to standard care.

CEL-SCI Corporation (NYSE American: CVM) has announced the closing of its public offering of 2,000,000 shares of common stock at $2.50 per share, raising gross proceeds of $5 million. The clinical stage cancer immunotherapy company has granted underwriters a 45-day option to purchase up to 190,000 additional shares for over-allotments. The net proceeds will fund the development of Multikine, general corporate purposes, and working capital. ThinkEquity served as the sole book-running manager for the offering, which was conducted under a shelf registration statement filed with the SEC.